NeoGenomics (NEO) Reports In-Line Q4 EPS, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
NeoGenomics Reports 40% Revenue Growth to $107 Million in the Fourth Quarter
February 27, 2020 7:10 AM ESTFourth-Quarter 2019 Highlights:
Consolidated revenue increased 39.7% to $106.9 millionClinical Services revenue increased 41.7% to $93.4 million Pharma Services revenue increased 27.5% to $13.5 millionPharma Services backlog increased 31.8% to $130.3 millionCompany issues 2020 financial guidanceFT. MYERS, FL / ACCESSWIRE / February 27, 2020 / NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today announced fourth-quarter and full-year 2019 results for the period ended December 31, 2019.
"Our fourth quarter performance concludes a very successful year for NeoGenomics in which our company grew by nearly 50%... More
